MAP2K5 and breast carcinoma: While Fra-1expression activates a mesenchymal phenotype in breast cancer [15], further data is requiredto further support a direct relationship between MEK5/ERK5 signaling and the Fra-1-drivenEMT phenotype in breast cancer.